Lecanemab, currently licensed as a biweekly 10 mg/kg IV infusion, is developed by Eisai and Biogen to address the unmet needs of AD patients. AD, a chronic, progressive disease and the UK’s leading ...

NICE reviewed various technologies and recommended DERM as the only AI tool suitable for NHS use. It is the first dermatology ...

Regeneron Pharmaceuticals has announced that the European Commission has conditionally approved Lynozyfic (linvoseltamab) for ...

Groundbreaking research has identified over 900 genetic links to osteoarthritis, including 500 previously undiscovered, in a ...

Groundbreaking research has identified over 900 genetic links to osteoarthritis, including 500 previously undiscovered, in a study involving Sheffield Teaching Hospitals NHS Foundation Trust.

At the heart of this evolution are Smart Hospitals – facilities that harness advanced technologies to enhance patient care, ...